Artificial oxygen carrier with pharmacologic actions of adenosine-5′-triphosphate, adenosine, and reduced glutathione formulated to treat an array of medical conditions

Artificial Organs

Volumn 38, Issue 8, 2014, Pages 684-690

  Simoni, Jan ^a,b   Simoni, Grace ^a,b   Moeller, John F ^a,b   Feola, Mario ^b   Wesson, Donald E ^c  

^a Texas HemoBioTherapeutics BioInnovation Center   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Adenosine; Adenosine 5 triphosphate; Anemia; Artificial oxygen carrier; Hemoglobin; Ischemia; Reduced glutathione

Indexed keywords

BLOOD; NITRIC OXIDE; OXYGEN; PEPTIDES;

'CURRENT; ADENOSINE; ADENOSINE-5-TRIPHOSPHATE; ANEMIA; ARTIFICIAL OXYGEN CARRIER; CROSS LINKING; HAEMOGLOBINS; ISCHAEMIA; MEDICAL CONDITIONS; REDUCED GLUTATHIONE;

HEMOGLOBIN;

ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; ANTIANEMIC AGENT; GLUTATHIONE; HEME; HEMOGLOBIN; HEMOTECH; NITRIC OXIDE; OXYGEN; POLYMER; PURINERGIC RECEPTOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; BLOOD SUBSTITUTE; POLYMERIZED HEMOGLOBIN;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEEDING; BLOOD VESSEL OCCLUSION; BLOOD VESSEL TONE; CATTLE; CEREBROVASCULAR ACCIDENT; CHEMICAL MODIFICATION; CONJUGATION; CORONARY ARTERY DISEASE; CROSS LINKING; DIMERIZATION; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; EXPERIMENTAL DOG; EXPERIMENTAL PIG; EXPERIMENTAL RABBIT; EXTRAVASATION; GENOTOXICITY; GLOMERULUS FILTRATION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; ISOELECTRIC POINT; MOUSE; NEOPLASM; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; RAT; RESTENOSIS; SICKLE CELL ANEMIA; THROMBOSIS; TOXICOLOGY; TRAUMATIC BRAIN INJURY; VASCULAR DISEASE; VASOCONSTRICTION; ANEMIA, SICKLE CELL; ANIMAL; METABOLISM;

ADENOSINE; ANEMIA, SICKLE CELL; ANIMALS; BLOOD SUBSTITUTES; GLUTATHIONE; HEME; HEMOGLOBINS; HUMANS; OXYGEN; RATS;

EID: 84906343436     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12337     Document Type: Article

References (43)

1. Klein HG. How safe is blood, really? Biologicals 2010;38:100-104.
2. Ironside JW. Variant Creutzfeld-Jakob disease: risk of transmission by blood transfusion and blood therapies. Haemophilia 2006;12(Suppl. 1):8-15.
3. World Health Organization. Ten facts on blood transfusion. 2013. Available at: http://www.who.int/features/factfiles/blood_transfusion/en/. Accessed February 28, 2014.
4. Lee JS, Gladwin MT. Bad blood: the risk of red cell storage. Nat Med 2010;16:381-382.
5. Shishehbor MH, Madhwal S, Rajagopal V, et al. Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2009;2:46-53.
6. Wang D, Sun J, Solomon SB, Klein HG, Natanson C. Transfusion of older stored blood and risk of death: a meta-analysis. Transfusion 2012;52:1184-1195.
7. Anderson HV, Leimgruber PP, Roubin GS, Nelson DL, Gruentzig AR. Distal coronary artery perfusion during percutaneous transluminal coronary angioplasty. Am Heart J 1985;110:720-726.
8. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. J Am Med Assoc 2008;299:2304-2312.
9. Silverman TA, Weiskopf RB. Planning Committee and the Speakers. Hemoglobin-based oxygen carriers: current status and future directions. Anesthesiology 2009;111:946-963.
10. Riess JG. Oxygen carriers ("blood substitutes")-raison d'etre, chemistry, and some physiology. Chem Rev 2001;101:2797-2920.
11. Simoni J, Simoni G, Moeller JF. Intrinsic toxicity of hemoglobin: how to counteract it. Artif Organs 2009;33:100-109.
12. Simoni J. Endothelial cell response to hemoglobin based oxygen carriers. Is the attenuation of pathological reactions possible? In: Kobayashi K, Tsuchida E, Horinouchi H, eds. Artificial Oxygen Carrier. Its Front Line. Verlag Tokyo-Berlin-Heidelberg-New York: Springer, 2005;75-125.
13. Kluger R. Red cell substitutes from hemoglobin-do we start all over again? Curr Opin Chem Biol 2010;14:538-543.
14. Alayash AI. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? Nat Biotechnol 1999;17:545-549.
15. Buehler PW, D'Agnillo F. Toxicological consequences of extracellular hemoglobin: biochemical and physiological perspectives. Antioxid Redox Signal 2010;12:275-291.
16. Moon-Massat P, Scultetus A, Arnaud F, et al. The effect HBOC-201 and sodium nitrite resuscitation after uncontrolled haemorrhagic shock in swine. Injury 2012;43:638-647.
17. Fonseca V, Avizinis J, Moon-Massat P, Freilich D, Kim HW, Hai CM. Differential sensitivities of pulmonary and coronary arteries to hemoglobin-based oxygen carriers and nitrovasodilators: study in a bovine ex vivo model of vascular strips. Vascul Pharmacol 2010;52:215-223.
18. Simoni J, Villanueva-Meyer J, Simoni G, Moeller JF, Wesson DE. Control of oxidative reactions of hemoglobin in the design of blood substitutes: role of the ascorbate-glutathione antioxidant system. Artif Organs 2009;33:115-126.
19. Simoni J. Artificial oxygen carriers: renewed commercial interest and scientific/technological advances. Artif Organs 2012 Feb;36:123-126.
20. Feola M, Simoni J, Canizaro PC: Blood Substitute. U.S. Patent No. 5, 439, 882. 1995.
21. Simoni J, Simoni G, Feola M: Methods of Treating Acute Blood Loss. U.S. Patent No. 7, 759, 306. 2010.
22. Simoni J, Simoni G, Moeller JF: Orthogonal Method for the Removal of Transmissible Spongiform Encephalopathy Agents From Biological Fluids. Patent Application US20110097746. Publication Date: 04/28/2011.
23. Simoni J, Simoni G, Moeller JF: Orthogonal Method for the removal of prions and viruses from hemoglobin solution. The XIII International Symposium on Blood Substitutes and Oxygen Therapeutics. Massachusetts General Hospital and Harvard Medical School, Boston, MA, July 27-29, 2011. Abstracts Book 2011;69(P-28).
24. Simoni J, Simoni G, Wesson DE, Feola M. ATP-adenosine-glutathione cross-linked hemoglobin as clinically useful oxygen carrier. Curr Drug Discov Technol 2012;9:173-187.
25. Ellsworth ML, Forrester T, Ellis CG, Dietrich HH. The erythrocyte as a regulator of vascular tone. Am J Physiol 1995;269(6 Pt 2):H2155-2161.
26. Simoni J, Simoni G, Martinez-Zaguilan R, et al. Improved blood substitute: evaluation of its effects on human endothelial cells. ASAIO J 1998;44:M356-367.
27. Simoni J, Simoni G, Lox CD, Prien SD, Shires GT. Modified hemoglobin solution, with desired pharmacological properties, does not activate nuclear transcription factor NF-kappa B in human vascular endothelial cells. Artif Cells Blood Substit Immobil Biotechnol 1997;25:193-210.
28. Simoni J, Simoni G, Lox CD, Prien SD, Tran R, Shires GT. Expression of adhesion molecules and von Willebrand factor in human coronary artery endothelial cells incubated with differently modified hemoglobin solutions. Artif Cells Blood Substit Immobil Biotechnol 1997;25:211-225.
29. Simoni J, Simoni G, Wesson DE, Griswold JA, Feola M. A novel hemoglobin-adenosine-glutathione based blood substitute: evaluation of its effects on human blood ex vivo. ASAIO J 2000;46:679-692.
30. Simoni J, Simoni G, Wesson DE, Griswold JA, Feola M. Attenuation of hemoglobin neurotoxic potential by cross-linking with adenosine and conjugation with reduced glutathione. Artif Cells Blood Substit Immobil Biotechnol 2001;29:128.
31. Simoni J, Simoni G, Wesson DE, Griswold JA, Moeller JF, Feola M. Combining hemoglobin with adenosine and reduced glutathione attenuates its direct and indirect neurotoxic potential. Artif Blood 2003;11:96.
32. Simoni J, Simoni G, Newman G, Feola M. An improved blood substitute. In vivo evaluation of its hemodynamic effects. ASAIO J 1996;42:M773-782.
33. Simoni J, Simoni G, Hartsell A, Feola M. An improved blood substitute. In vivo evaluation of its renal effects. ASAIO J 1997;43:M714-725.
34. Simoni J, Simoni G, Wesson DE, Griswold JA, Feola M. Oxidative reactions of hemoglobin cross-linked with adenosine and conjugated with reduced glutathione. Artif Cells Blood Substit Immobil Biotechnol 2001;29:164.
35. Simoni J, Simoni G, Griswold JA, Moeller JF, Wesson DE. Activatory and suppressive roles of hemoglobin-based blood substitutes at the transcriptional level. ASAIO J 2003;49:181.
36. Simoni J, Simoni G, Griswold JA, Moeller JF, Feola M, Wesson DE. Response of human microvascular endothelium to acellular hemoglobin in ischemia. A comparison study. In: Greenburg AG, Kim HW, eds. Proceedings from the Xth International Symposium on Blood Substitutes. Providence, RI: Brown University, June 12-15, 2005;150.
37. 2a, a vasoconstrictive isoprostane. Artif Cells Blood Substit Immobil Biotechnol 2001;29:162.
38. HemoTech. GLP Preclinical Toxicological Tests. Final Reports: RTC Research Toxicology Centre S.p.A., Pompesia, Rome, Italy. 1992.
39. Feola M, Simoni J, Angelillo R, et al. Clinical trial of a hemoglobin based blood substitute in patients with sickle cell anemia. Surg Gynecol Obstet 1992;174:379-386.
40. Simoni J, Simoni G, Moeller JF, Feola M, Griswold JA, Wesson DE. Adenosine-5′-triphosphate-adenosine-glutathione cross-linked hemoglobin as erythropoiesis-stimulating agent. Artif Organs 2012;36:139-150.
41. Simoni J, Simoni G, Moeller JF, Kumar A, Roongsritong C, Meyerrose GE. HemoTech-blood substitute role in the prevention of platelet activation in percutaneous coronary intervention (PCI) patients. ASAIO J 2010;56:138.
42. Simoni J, Simoni G, Griswold JA, Moeller JF, Wesson DE. Hemoglobin, transcriptional activator and suppressor. How to tip the balance? Artif Blood 2003;11:69.
43. Klein HG. Blood substitutes: how close to a solution? Oncology (Williston Park) 2002;16(9 Suppl. 10):147-151.